How are VKTX strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VKTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 80.32%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$542.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a VKTX strangle?

The breakeven for the VKTX strangle priced on this page is roughly $31.58 and $46.43 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VKTX market-implied 1-standard-deviation expected move is approximately 23.03%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current VKTX implied volatility affect this strangle?

VKTX ATM IV is at 80.32% with IV rank near 27.63%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

VKTX Strangle Strategy

VKTX (Viking Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy.

VKTX (Viking Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.42B, a beta of 0.68 versus the broader market, a 52-week range of 22.959-43.15, average daily share volume of 2.3M, a public-listing history dating back to 2015, approximately 45 full-time employees. These structural characteristics shape how VKTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.68 indicates VKTX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on VKTX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current VKTX snapshot

As of June 30, 2026, spot at $39.46, ATM IV 80.32%, IV rank 27.63%, expected move 23.03%. The strangle on VKTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 31-day expiry.

Why this strangle structure on VKTX specifically: VKTX IV at 80.32% is on the cheap side of its 1-year range, which favors premium-buying structures like a VKTX strangle, with a market-implied 1-standard-deviation move of approximately 23.03% (roughly $9.09 on the underlying). The 31-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VKTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on VKTX should anchor to the underlying notional of $39.46 per share and to the trader's directional view on VKTX stock.

VKTX strangle setup

The VKTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VKTX near $39.46, the first option leg uses a $41.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VKTX chain at a 31-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VKTX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$41.00	$3.55
Buy 1	Put	$37.00	$1.88

VKTX strangle risk and reward

Net Premium / Debit: -$542.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$542.50
Breakeven(s): $31.58, $46.43
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

VKTX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on VKTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$3,156.50
$8.73	-77.9%	+$2,284.13
$17.46	-55.8%	+$1,411.76
$26.18	-33.7%	+$539.38
$34.90	-11.5%	-$332.99
$43.63	+10.6%	-$279.64
$52.35	+32.7%	+$592.73
$61.08	+54.8%	+$1,465.10
$69.80	+76.9%	+$2,337.47
$78.52	+99.0%	+$3,209.85

When traders use strangle on VKTX

Strangles on VKTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VKTX chain.

VKTX thesis for this strangle

The market-implied 1-standard-deviation range for VKTX extends from approximately $30.37 on the downside to $48.55 on the upside. A VKTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current VKTX IV rank near 27.63% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on VKTX at 80.32%. As a Healthcare name, VKTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VKTX-specific events.

VKTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VKTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VKTX alongside the broader basket even when VKTX-specific fundamentals are unchanged. Always rebuild the position from current VKTX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on VKTX?: A strangle on VKTX is the strangle strategy applied to VKTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With VKTX stock trading near $39.46, the strikes shown on this page are snapped to the nearest listed VKTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are VKTX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the VKTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 80.32%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$542.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a VKTX strangle?: The breakeven for the VKTX strangle priced on this page is roughly $31.58 and $46.43 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VKTX market-implied 1-standard-deviation expected move is approximately 23.03%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on VKTX?: Strangles on VKTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the VKTX chain.
How does current VKTX implied volatility affect this strangle?: VKTX ATM IV is at 80.32% with IV rank near 27.63%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.